Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT02726750
Status
Recruiting
Apply to this trial

Conditions

  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Plasma Cell Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biospecimen Collection — PROCEDURE
    Undergo collection of blood samples
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies

Study Details

The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.

Key Dates

Start date
Dec 14, 2015
Status verified
Apr 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Observational (biospecimen collection)
    Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.

Primary Outcome Measure

Rate of progression to multiple myeloma (MM) [ Time Frame: 3 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030
Mei Huang
[email protected]
713-745-9901
Krina Patel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
M D Anderson Cancer Center· Houston, TX

Related Studies